GLP-1 drugs and hair loss: semaglutide and tirzepatide carry the clearest signal

Hair loss has circulated as an anecdotal side effect of GLP-1 receptor agonists since the drugs' obesity indications made them widely used, but it isn't listed prominently in most prescribing information. A systematic review published this month in Science Progress pulls together the pharmacovigilance and clinical evidence that exists so far [s1].

The design

Researchers searched PubMed, Embase, Scopus, and Web of Science following PRISMA guidelines, with the review protocol registered in advance on PROSPERO [s1]. Of 133 studies identified, 24 met the inclusion criteria: primary articles specifically assessing hair loss associated with GLP-1 receptor agonist use [s1].

What it found

Among the GLP-1 drugs studied, semaglutide and tirzepatide showed the highest incidence rates of hair loss and the most frequent safety signals in pharmacovigilance databases — systems that track adverse events reported after a drug reaches the market [s1]. Liraglutide, dulaglutide, lixisenatide, and exenatide were assessed in fewer studies and, where data existed, showed lower reported hair loss risk than semaglutide and tirzepatide [s1].

Two subtypes of hair loss predominated where classification was available: androgenetic alopecia (the pattern-baldness type, driven by genetics and hormones) and telogen effluvium (diffuse shedding, typically triggered by a physical stressor to the body) [s1]. Tirzepatide — the drug associated with the largest average weight loss among those studied — was most frequently linked specifically to telogen effluvium [s1]. Semaglutide's hair loss association appeared dose-dependent: doses under 2 mg weekly were rarely implicated, while the higher doses used specifically for obesity treatment were more commonly associated with reports of hair loss [s1]. Women appeared disproportionately affected across the studies reviewed [s1].

The mechanism the review points to

The review's authors identify rapid weight loss itself as a likely contributor, particularly to telogen effluvium [s1]. Telogen effluvium is a recognized phenomenon following major physiological stressors more broadly — significant weight loss, illness, surgery, or childbirth can all trigger it, because it reflects hair follicles being pushed prematurely into a resting (telogen) phase before shedding. That framing would mean the hair loss associated with these drugs is, at least in part, a downstream consequence of how much and how fast weight comes off, rather than a direct pharmacological effect of the drug on hair follicles — though the review does not claim to have fully separated those two possibilities.

What the evidence doesn't establish

This is a systematic review of existing, mostly observational, evidence — pharmacovigilance reports, clinical case data, and cohort studies of varying design and quality, rather than a single controlled study measuring hair loss as a primary trial endpoint. Pharmacovigilance data specifically is a weak tool for measuring true incidence, since it depends on unprompted, voluntary reporting rather than systematic follow-up of everyone taking a drug — meaning both underreporting and reporting bias (people are more likely to report a side effect if they suspect a link) can distort the picture. The review's authors themselves state that further studies are needed to clarify the underlying cause of drug-induced weight loss-related hair loss, identify which patients are most vulnerable, and establish causality and timing through large, prospective randomized trials [s1] — an explicit acknowledgment that the current evidence base falls short of proving these drugs directly cause hair loss, as opposed to weight loss speed being the more direct trigger.

What to watch

Whether future GLP-1 trials begin systematically tracking hair loss as a prespecified outcome, which would generate more reliable incidence estimates than pharmacovigilance databases can provide, and whether the sex disparity noted here holds up in better-controlled data. This article is not medical advice.

Sources

1. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling — Science Progress, 17 April 2026